Pfizer Inc. (NYSE:PFE) announced that its phase 2 randomized study, PALOMA-1, of palbociclib combined with letrozole, achieved its primary endpoint. Pfizer Inc. (NYSE:PFE) shares after opening at $31.26 moved to $31.39 on last trade day and at the end of the day closed at $30.87. Company price to sales ratio in past twelve months was calculated as 3.83 and price to cash ratio as 6.09. Pfizer Inc. (NYSE:PFE) showed a negative weekly performance of -3.38%.
Bristol-Myers Squibb Company (NYSE:BMY) announced that it has filed new drug applications (NDAs) with the U.S. Food and Drug Administration (FDA) for hepatitis C virus (:HCV) candidates, daclatasvir (:DCV) and asunaprevir (:ASV). While daclatasvir belongs to a new class of drugs- NS5A inhibitors- asunaprevir is a NS3 protease inhibitor. Bristol-Myers Squibb Co (NYSE:BMY) shares fell -2.43% in last trading session and ended the day on $49.06. BMY return on equity ratio is recorded as 17.70% and its return on assets is 6.90%. Bristol-Myers Squibb Co (NYSE:BMY) yearly performance is 23.70%.
A couple of days back, Merck & Co. Inc. (NYSE:MRK) presented early findings from studies assessing the efficacy of its oncology candidate, MK-3475, an anti-PD-1 immunotherapy, in patients suffering from advanced melanoma and advanced non-small cell lung cancer (NSCLC). The data was presented at the American Association for Cancer Research’s (AACR) annual meeting. Merck & Co., Inc. (NYSE:MRK) shares moved down -0.27% in last trading session and was closed at $55.04, while trading in range of $54.70 – $55.61. Merck & Co., Inc. (NYSE:MRK) year to date (YTD) performance is 10.83%.
Johnson & Johnson (NYSE:JNJ) sells a massive variety of products from Band-Aids and Tylenol to joint reconstruction products. This diversification gives JNJ’s profits a greater consistency than other companies. When one product struggles, it has others to make up the difference. This consistency explains why JNJ has grown after-tax profit (NOPAT) by 10% compounded annually for the past 15 years. Its NOPAT has not declined in any year over that timeframe. Johnson & Johnson (NYSE:JNJ) weekly performance is 0.12%. On last trading day company shares ended up $98.06. Johnson & Johnson (NYSE:JNJ) distance from 50-day simple moving average (SMA50) is 5.76%. Analysts mean target price for the company is $101.08.
Leave a Reply